By Iain Gilbert
Date: Monday 16 Nov 2026
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its rare disease division Alexion had secured regulatory approvals for Klygefa (gefurulimab) in both the European Union and the United States for the treatment of adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive.
| Baxfendy recommended for approval in the EU | 16-Nov-2026 | 07:15 | RNS |
| Imfinzi + EV approved in US in bladder cancer | 16-Nov-2026 | 07:10 | RNS |
| Klygefa (gefurulimab) approved in the US | 16-Nov-2026 | 07:05 | RNS |
| Klygefa (gefurulimab) approved in the EU | 16-Nov-2026 | 07:00 | RNS |
| Admission of Further Securities to Trading | 02-Nov-2026 | 15:05 | RNS |
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 13,304.00p |
| Change Today | -342.00p |
| % Change | -2.51 % |
| 52 Week High | 15,316.00 |
| 52 Week Low | 11,460.00 |
| Volume | 2,039,675 |
| Shares Issued | 1,551.07m |
| Market Cap | £206,354m |
| Beta | 0.00 |
| RiskGrade | 123 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income |
|
|---|
| Growth |
|
|---|
| Strong Buy | 10 |
| Buy | 8 |
| Neutral | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| 1st Interim | 2nd Interim | |
| Ex-Div | 06-Aug-26 | 19-Feb-26 |
| Paid | 08-Sep-26 | 23-Mar-26 |
| Amount | 106.00¢ | 217.00¢ |
| Time | Volume / Share Price |
| 09:57 | 285,932 @ 13,672.00p |
| 16:40 | 50,000 @ 13,308.60p |
| 16:37 | 1,200 @ 13,304.00p |
| 16:36 | 1,200 @ 13,304.00p |
| 16:36 | 1,200 @ 13,304.00p |
You are here: research